Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maya Vaysbrot

Neurology Glendale, AZ Doctor of Osteopathy

NPI 1902063837 CMS profile 221613

20325 N. 51St. Ave., Suite 160, Glendale, AZ 85308

Open in the dashboard

General payments

$5,549

256 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maya Vaysbrot of Glendale, AZ is reported in the CMS Open Payments database as having received $5,549 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,451 75
2024 General $859 59
2023 General $726 38
2022 General $400 22
2021 General $469 22
2020 General $141 9
2019 General $504 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maya Vaysbrot
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Maya Vaysbrot were reported at $2,451. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Maya Vaysbrot Neurology median Middle half National median
2019 $504 $474 $118–$2,177 $163
2020 $141 $367 $82–$2,309 $114
2021 $469 $438 $104–$2,547 $132
2022 $400 $442 $103–$2,388 $149
2023 $726 $464 $119–$2,312 $160
2024 $859 $468 $119–$2,323 $164
2025 $2,451 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,228 119 payments
  2. Neuronetics, Inc. $924 2 payments
  3. Pfizer Inc. $320 27 payments
  4. UCB, Inc. $182 11 payments
  5. Alexion Pharmaceuticals, Inc. $152 9 payments
  6. Teva Pharmaceuticals USA, Inc. $134 6 payments
  7. Axsome Therapeutics, Inc. $121 1 payment
  8. Amgen Inc. $110 6 payments
  9. Argenx US, Inc. $86 3 payments
  10. Biogen, Inc. $82 4 payments
  11. Other $1,208 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,219 255 payments
  2. Travel and Lodging $330 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $1,219 64 payments
  2. Neurostar TMS Therapy System $924 2 payments
  3. QULIPTA $888 50 payments
  4. BOTOX Botox Therapeutic $392 26 payments
  5. NURTEC ODT $320 27 payments
  6. ZAVZPRET $320 27 payments
  7. BOTOX Neuroscience $189 6 payments
  8. DUOPA $157 9 payments
  9. Zilbrysq $156 8 payments
  10. AIMOVIG $151 10 payments
  11. Other $2,107 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

995

Median for Neurology: 833

Drug cost

$25,416

Median for Neurology: $202,670

Branded share of claims

11.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Generic 117 $4,143
Rivastigmine Generic 23 $3,459
Donepezil Hcl Generic 222 $2,715
Rivastigmine Rivastigmine Tartrate Brand 27 $2,285
Propranolol Hcl Er Propranolol Hcl Brand 22 $1,942
Duloxetine Hcl Generic 55 $1,822
Sumatriptan Succinate Generic 24 $1,204
Divalproex Sodium Generic 12 $1,082
Gabapentin Generic 92 $1,048
Pregabalin Generic 23 $942

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$145,961

Of which drugs: $43,017

Medicare patients

390

Average age 75

Services billed

9,930

224 women, 166 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 55%
Depression 30%
Ischemic heart disease 27%
Diabetes 23%
Chronic kidney disease 23%
Osteoporosis 20%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 19 8,800 $40,967

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $164
$164 — —
BOTOX
  • AbbVie, Inc. $118
$118 — 8,800
QULIPTA
  • AbbVie, Inc. $104
$104 — —
NURTEC ODT
  • PFIZER INC. $77
$77 — —
ZAVZPRET
  • PFIZER INC. $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record